WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, underscoring the company's enduring commitment to responsible business practices and supply chain resilience....
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering...
Neusoft Education officially renamed as ” Neutech Group Limited “, accelerating the advancement of the “education-healthcare-wellness and mind tour” strategy in a new stage
HONG KONG, Jan. 11, 2025 /PRNewswire/ -- On 9 January, Neusoft Education (09616.HK) announced that the Company's English name will change from "Neusoft Education Technology Co. Limited" to "Neutech Group Limited". The name change will take effect on the same day. According to the announcement, the Company's renaming to "Neutech Group Limited" better reflects its strategic transformation and upgrade, and...
Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs
The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformative S$5.5 million gift towards research. The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 /PRNewswire/ -- Duke-NUS Medical School celebrated its 20th anniversary with a significant philanthropic milestone, securing more...
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agreement") with Windward Bio AG ("Windward Bio") for SKB378/HBM9378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) jointly developed by...
Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution
IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ -- Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material designed to combat the global plastic pollution crisis. Accompanying this launch is the release of the CornNext-17 White Paper, a detailed report that highlights the revolutionary features of CornNext-17, its potential to replace...
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025 CAMBRIDGE, Mass., Jan. 11,...
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement, Menarini Group will be granted global rights to develop and commercialize the asset. The deal...
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the Company and Sichuan Kelun Biotech BioPharmaceutical (HKEX: 06990, "Kelun-Biotech") have entered into...
Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress
Announces Major Milestones at the JPM Healthcare Conference SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company's growth, sharpened focus on neuroscience, and commitment to delivering innovative therapies for psychiatric and neurological disorders. Reimagining Neurotherapeutics At the heart of Xylo's innovation...
